BioSpace News Archive

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023.

Stevanato Group S.p.A. announced that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m.

Ventus Therapeutics, Inc. announced the details of two presentations to be made at the Keystone Symposium on Innate Immunity: From Innate Sensing to Adaptive Responses, being held April 16-19 in Snowbird, Utah.

Sonnet BioTherapeutics Holdings, Inc. announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients ( NCT05352750 ) on Tuesday, April 18, 2023 at 5:00 pm ET.

Heart Test Laboratories, Inc. d/b/a HeartSciences today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

Shionogi & Co., Ltd. announces key data for Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 15-18, 2023, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.

Pipeline Therapeutics announced today that it has entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical.

Boundless Bio today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.

Dr. Lucy E.M. Finnigan will present on the Phase 2a clinical trial of AXA1125 in Long COVID Fatigue on April 18.